

# **Clinical trial results:**

# A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Summary

Results information		

#### **Trial information**

**Trial identification** 

### Additional study identifiers

Au	Additional study identifiers		
		•	

#### Sponsors

Paediatric regulatory details		

Results analysis stage		

### General information about the trial

# Population of trial subjects


Subjects enrolled per country		

Subjects enrolled per age group		

# Subject disposition

# Recruitment Pre-assignment

Period 1
\_\_\_\_\_\_
\_\_\_\_\_
\_\_\_\_\_
\_\_\_\_\_
\_\_\_\_\_
Arms
\_\_\_\_\_\_
Arm title



Number of subjects in period 1	

# Reporting groups

Reporting group values		

	•		


Primary: Overall Survival: Stratified by Histology - Squamous vs. Non-Squamous Tumor Histology

End point values		

## Statistical analyses

Statistical analysis title	
----------------------------	--


Statistical analysis title	
Statistical analysis title	





#### Adverse events information


Dictionary used
Reporting groups


Serious adverse events		














Non-serious adverse events			

# More information

# Substantial protocol amendments (globally)

Date	Amendment

Interruptions (globally)

Limitations and caveats